

NASH PHARMACY LIMITED

Abridged Accounts

Period of accounts

Start date: 01 April 2021

End date: 31 March 2022

Amended

TUESDAY



AC7IMEYD

A23

11/07/2023

#31

COMPANIES HOUSE

NASH PHARMACY LIMITED
Contents Page
For the year ended 31 March 2022

Accountants' report	3
Statement of financial position	4
Notes to the financial statements	6

Amended

NASH PHARMACY LIMITED
Accountants' Report
For the year ended 31 March 2022

Accountants' report on the financial statements to the directors of Nash Pharmacy Limited.

In accordance with our terms of engagement and in order to assist you to fulfill your duties under the Companies Act 2006, we have compiled the financial statements of the company for the period ending year ended 31 March 2022 which comprise of the Profit and Loss Account, the Balance Sheet and the related notes from the accounting records and information and explanations you have given to us.

This report is made to the company's Board of Directors, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's Board of Directors that we have done so and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's Board of Directors, as a body, for our work or for this report.

You have acknowledged on the Balance Sheet as at year ended 31 March 2022 your duty to ensure that the company has kept the correct accounting records to prepare financial statements that give a true and fair view under the Companies Act 2006. You consider that the company is exempt from statutory requirement for an audit for the period.

We have not been instructed to carry out an audit of the financial statements. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.

.....
Stonebridge Accountants
19a Chorley Old Road
Bolton
BL1 3AD
12 June 2023

NASH PHARMACY LIMITED
Statement of Financial Position
As at 31 March 2022

	Notes	2022 £	2021 £
Fixed assets			
Intangible fixed assets	3	72,938	75,078
Tangible fixed assets	4	407,934	371,861
		480,872	446,939
Current assets			
Stocks		270,729	218,676
Debtors		693,708	727,039
Cash at bank and in hand		314,182	248,226
		1,278,619	1,193,941
Creditors: amount falling due within one year		(229,879)	(93,713)
Net current assets		1,048,740	1,100,228
Total assets less current liabilities		1,529,612	1,547,167
Creditors: amount falling due after more than one year		(149,664)	(228,922)
Provisions for liabilities		(12,144)	(5,774)
Net assets		1,367,804	1,312,471
Capital and reserves			
Called up share capital	5	100	100
Profit and loss account		1,367,704	1,312,371
Shareholder's funds		1,367,804	1,312,471

For the year ended 31 March 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:


1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
2. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of Part 15 of the Companies Act 2006. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).

NASH PHARMACY LIMITED
Statement of Financial Position
As at 31 March 2022

The financial statements were approved by the board of directors on 12 June 2023 and were signed on its behalf by:



Mr Naresh Chhotubhai Patel
Director

Amended

NASH PHARMACY LIMITED
Notes to the Abridged Financial Statements
For the year ended 31 March 2022

General Information

Nash Pharmacy Limited is a private company, limited by shares, registered in England & Northern Ireland, registration number 02278935, registration address 61/63 Castle Street, Bolton, Lancashire, BL2 1AD.

The presentation currency is £ sterling.

1. Accounting policies

Significant accounting policies

Statement of compliance

These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

Basis of preparation

The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.

The financial statements are prepared in sterling which is the functional currency of the company.

Turnover

Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.

Taxation

Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves.

The company's liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Current and deferred tax assets and liabilities are not discounted.

Deferred taxation

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the reporting date.

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Current and deferred tax assets and liabilities are not discounted.

Dividends

Proposed dividends are only included as liabilities in the statement of financial position when their payment has been approved by the shareholders prior to the statement of financial position date.

Intangible assets

Intangible assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight line basis over their estimated useful economic lives. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.

Goodwill

Acquired goodwill is stated at cost less amortisation. Amortisation is calculated on a straight line basis over the estimated expected useful economic life of the goodwill of years.

NASH PHARMACY LIMITED
Notes to the Abridged Financial Statements
For the year ended 31 March 2022

Tangible fixed assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Land and Buildings	2% Reducing Balance
Property Improvements	15% Reducing Balance
Motor Vehicles	25% Reducing Balance
Fixtures and Fittings	15% Reducing Balance
Computer Equipment	25% Reducing Balance

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

Provisions

Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.

2. Average number of employees

Average number of employees during the year was 17 (2021 : 17).

3. Intangible fixed assets

Cost	Goodwill £	Total £
At 01 April 2021	107,000	107,000
Additions	-	-
Disposals	-	-
At 31 March 2022	<u>107,000</u>	<u>107,000</u>
Amortisation		
At 01 April 2021	31,922	31,922
Charge for year	2,140	2,140
On disposals	-	-
At 31 March 2022	<u>34,062</u>	<u>34,062</u>
Net book values		
At 31 March 2022	<u>72,938</u>	<u>72,938</u>
At 31 March 2021	<u>75,078</u>	<u>75,078</u>

NASH PHARMACY LIMITED
Notes to the Abridged Financial Statements
For the year ended 31 March 2022

4. Tangible fixed assets

Cost or valuation	Land and Buildings	Property Improvements	Motor Vehicles	Fixtures and Fittings	Computer Equipment	Total
	£	£	£	£	£	£
At 01 April 2021	65,000	373,439	29,647	425,225	4,322	897,633
Additions	-	-	35,692	29,166	-	64,858
Disposals	-	-	(13,985)	-	-	(13,985)
At 31 March 2022	65,000	373,439	51,354	454,391	4,322	948,506
Depreciation						
At 01 April 2021	18,896	95,411	24,355	384,347	2,763	525,772
Charge for year	1,300	7,469	8,197	7,004	390	24,360
On disposals	-	-	(9,560)	-	-	(9,560)
At 31 March 2022	20,196	102,880	22,992	391,351	3,153	540,572
Net book values						
Closing balance as at 31 March 2022	44,804	270,559	28,362	63,040	1,169	407,934
Opening balance as at 01 April 2021	46,104	278,028	5,292	40,878	1,559	371,861

5. Share Capital

Authorised
100 Class A shares of £1.00 each

Allotted, called up and fully paid

100 Class A shares of £1.00 each

	2022	2021
	£	£
	100	100
	100	100